Management of hepatitis C virus genotype 4: recommendations of an international expert panel

J Hepatol. 2011 Jun;54(6):1250-62. doi: 10.1016/j.jhep.2010.11.016. Epub 2010 Dec 8.

Abstract

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in the world, it has not been the subject of widespread research. Therefore, this document, drafted by a panel of international experts, aimed to review current knowledge on the epidemiology, natural history, clinical, histological features, and treatment of HCV-4 infections.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Carcinoma, Hepatocellular / etiology
  • Clinical Trials as Topic
  • Genotype
  • Hepacivirus / classification*
  • Hepacivirus / genetics*
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / etiology
  • Hepatitis C, Chronic / therapy*
  • Hepatitis C, Chronic / virology*
  • Humans
  • Interferon Type I / therapeutic use
  • Interferons
  • Interleukins / genetics
  • Liver Neoplasms / etiology
  • Liver Transplantation
  • Polymorphism, Single Nucleotide
  • Practice Guidelines as Topic
  • Recombinant Proteins
  • Ribavirin / therapeutic use

Substances

  • Antiviral Agents
  • interferon-lambda, human
  • Interferon Type I
  • Interleukins
  • Recombinant Proteins
  • Ribavirin
  • Interferons